A Phase 1 interventional study of Repaglinide and Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Day 1: Participants received single dose of 0.5 mg repaglinide tablet.
Drug: Repaglinide
* Day 1 to Day 9: Participants received 160 mg Selpercatinib capsule twice daily (BID). * Day 10: Participant received 160 mg Selpercatinib capsules BID co-administered with a single oral dose of 0.5 mg Repaglinide tablet on the morning of Day 10.
Drug: Repaglinide · Drug: Selpercatinib
Administered orally.
Administered orally.
Also known as: LY3527723, LOXO-292
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Maximum Observed Concentration (Cmax) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide
PK: CL/F of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide
Time frame: Period 1: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose); Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 hours post dose)
PK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib
Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib
Time frame: Period 2: Day 1 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib
Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib
Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Selpercatinib
Time frame: Period 2: Predose at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9
PK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib
Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
PK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib
Time frame: Period 2: Day 10 (Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post dose)
| Milestone | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| Started | 16 | 0 |
| Safety analysis population (received at least one dose of study drug) | 16 | 0 |
| Completed | 16 | 0 |
| Not completed | 0 | 0 |
| Milestone | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| Started | 0 | 16 |
| Safety analysis population (received at least one dose of study drug) | 0 | 16 |
| Completed | 0 | 13 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 3 |
| nanogram*hour per milliliter (ng*h/mL) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Repaglinide | 9.409 ± 57.1 | 26.87 ± 53.2 |
| nanogram*hour per milliliter (ng*h/mL) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide | 10.15 ± 51.3 | 27.31 ± 53.6 |
| percent AUC extrapolation | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide | 1.256 ± 43.8 | 1.258 ± 85.8 |
| nanogram per milliliter (ng/mL) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Repaglinide | 6.600 ± 77.4 | 12.11 ± 42.7 |
| hours | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Time to Reach Maximum Observed Concentration (Tmax) of Repaglinide | 0.623 ± 47.3 | 0.854 ± 42.5 |
| One per hour (1/h) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Apparent Terminal Elimination Rate Constant (Kel) of Repaglindide | 0.2406 ± 27.9 | 0.2036 ± 36.2 |
| hours | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Apparent First-order Terminal Elimination Half-life (t½) of Repaglinide | 2.881 ± 27.9 | 3.405 ± 36.2 |
PK: CL/F of Repaglinide
| Liter per Hour (L/h) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Repaglinide | 49.26 ± 51.3 | 18.31 ± 53.6 |
| Liter (L) | Period 1: Repaglinide | Period 2: Selpercatinib + Repaglinide |
|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Repaglinide | 204.8 ± 53.6 | 89.92 ± 64.9 |
| ng*h/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to the 12 Hour (AUC0-12) of Selpercatinib | 8424 ± 56.6 |
| ng*h/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 8396 ± 56.7 |
| ng/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib | 1476 ± 66.3 |
| hours | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Time to Reach Maximum Observed Concentration (Tmax) of Selpercatinib | 1.553 ± 25.9 |
| ng*h/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Area Under the Concentration-time Curve During a Dosing Interval (Tau) at Steady State (AUCtau) of Selpercatinib | 33960 ± 45.0 |
| ng/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Maximum Observed Concentration at Steady-state (Cmax,ss) of Selpertcatinib | 4082 ± 40.8 |
| ng/mL | Period 2: Selpercatinib + Repaglinide |
|---|---|
| Day 1 | 983.2 ± 225.43 |
| Day 2 | 1509 ± 362.03 |
| Day 3 | 1664 ± 529.60 |
| Day 4 | 1842 ± 657.65 |
| Day 5 | 1971 ± 642.36 |
| Day 6 | 2039 ± 780.35 |
| Day 7 | 2160 ± 771.22 |
| Day 8 | 2034 ± 635.04 |
| Day 9 | 2085 ± 762.09 |
| hours | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Time to Reach Maximum Observed Concentration at Steady-state (Tmax,ss) of Selpercatinib | 1.888 ± 29.6 |
| Liter per Hours (L/h) | Period 2: Selpercatinib + Repaglinide |
|---|---|
| PK: Apparent Total Plasma Clearance at Steady State After Oral/Extravascular Administration (CL,ss/F) of Selpercatinib | 4.711 ± 45.0 |
Collected over Baseline to Follow-up (up to Day 2 for Period 1; up to Day 11 for Period 2). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Repaglinide (Day 1) | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Period 2: Selpercatinib (Day 1 to Day 9) | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Period 2: Selpercatinib + Repaglinide (Day 10) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Event | Period 1: Repaglinide (Day 1) | Period 2: Selpercatinib (Day 1 to Day 9) | Period 2: Selpercatinib + Repaglinide (Day 10) |
|---|---|---|---|
| Blood glucose decreasedInvestigations | 5/16 | 0/16 | 8/13 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/16 | 0/16 | 3/13 |
| HeadacheNervous system disorders | 0/16 | 2/16 | 2/13 |
| PainGeneral disorders | 0/16 | 0/16 | 1/13 |
| NauseaGastrointestinal disorders | 0/16 | 0/16 | 1/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/16 | 0/16 | 1/13 |
| Electrocardiogram QT prolongedInvestigations | 0/16 | 1/16 | 0/13 |
| DizzinessNervous system disorders | 0/16 | 1/16 | 0/13 |
| TremorNervous system disorders | 1/16 | 0/16 | 0/13 |
| FatigueGeneral disorders | 0/16 | 1/16 | 0/13 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 37.2 ± 10.62 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 3 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Mar 2019, 1 month.
Results were first posted in Dec 2025, 6 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Repaglinide